tiprankstipranks
Eliem Therapeutics (ELYM)
NASDAQ:ELYM
US Market
Holding ELYM?
Track your performance easily

Eliem Therapeutics (ELYM) Ownership - Who Owns Eliem Therapeutics?

47 Followers

Eliem Therapeutics (ELYM) Ownership Overview

8.56%0.78%67.49%21.00%
67.49% Other Institutional Investors
― ETFs
21.00% Public Companies and
Individual Investors
The ownership structure of Eliem Therapeutics (ELYM) stock is a mix of institutional, retail, and individual investors. , 8.56% is owned by Insiders, and 21.00% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Jul 23, 2024
Valerie Morisset
Evp, R&d And Cso
xxxxxxxxxxxxx
$988495
Jul 19, 2024
Valerie Morisset
Evp, R&d And Cso
xxxxxxxxxxxxx
$289492
Jul 17, 2024
Valerie Morisset
Evp, R&d And Cso
xxxxxxxxxxxxx
$356500
Jul 16, 2024
Valerie Morisset
Evp, R&d And Cso
xxxxxxxxxxxxx
$650563

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2024
xxxxxxxxxxxxx
$157785
Jun 30, 2024
xxxxxxxxxxxxx
$4948965
Jun 30, 2024
xxxxxxxxxxxxx
$223390988

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
31,419,267Institution46.85%162,123,418
1,022,440Institution1.52%5,275,790
696,057Institution1.04%3,591,654
381,443Institution0.57%1,968,246
284,431Institution0.42%1,467,664
78,662Institution0.12%405,896
69,778Institution0.10%360,054
53,323Institution0.08%275,147
22,192Institution0.03%114,511
17,128Institution0.03%88,380

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
284,431Institution0.42%1,467,664
78,662Institution0.12%405,896
69,778Institution0.10%360,054
53,323Institution0.08%275,147
17,128Institution0.03%88,380
9,862Institution0.01%50,888
5,185Institution<0.01%26,755
2,618Institution<0.01%13,509
1,669Institution<0.01%8,612
935Institution<0.01%4,825

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
678,860Institution1.01%3,462,186
228,348Institution0.34%1,596,153
257,469Institution0.38%1,328,540
119,083Institution0.18%832,390
67,504Institution0.10%344,270
29,314Institution0.04%204,905
16,064Institution0.02%81,926
14,909Institution0.02%76,036
13,857Institution0.02%70,671
4,698Institution<0.01%32,839

FAQ

Who Owns Eliem Therapeutics (ELYM)?
According to the latest TipRanks data, approximately 67.49% of the company's stock is held by institutional investors, 8.56% is held by insiders, and 21.00% is held by retail investors.
    What percentage of Eliem Therapeutics (ELYM) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 67.49% of Eliem Therapeutics (ELYM) stock is held by institutional investors.
      What percentage of Eliem Therapeutics (ELYM) stock is held by retail investors?
      According to the latest TipRanks data, approximately 21.00% of Eliem Therapeutics (ELYM) stock is held by retail investors.
        Who owns the most shares of Eliem Therapeutics (ELYM)?
        Peter Kolchinsky owns the most shares of Eliem Therapeutics (ELYM).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis